ProMIS Neurosciences (NASDAQ: PMN) — Perfil da empresa, notícias e dados financeiros
ProMIS Neurosciences develops treatments for neurodegenerative diseases, using proprietary technology to target misfolded proteins.
ProMIS Neurosciences
ProMIS Neurosciences (TSX:PMN), (NASDAQ:PMN) focuses on discovering and developing treatments targeting neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. This company aims to identify specific epitopes on misfolded proteins which are common in these conditions, leveraging their proprietary technology platforms to create both therapeutic and diagnostic solutions. Their portfolio includes several antibody candidates in preclinical development, designed to target toxic misfolded protein aggregates believed to contribute to the progression of neurodegenerative diseases. The ultimate objective of ProMIS Neurosciences is to halt disease progression and improve the quality of life for patients suffering from these devastating conditions.
Resumo
Operações
Produtos e/ou serviços de ProMIS Neurosciences
- Development of precision medicine therapies targeting misfolded proteins implicated in neurodegenerative diseases like Alzheimer's and ALS.
- Research on monoclonal antibodies targeting toxic oligomers for the treatment of ALS and Alzheimer's disease.
- PMN310, an antibody therapy showing high selectivity for toxic amyloid-beta oligomers in Alzheimer's disease.
- Collaboration with pharmaceutical companies to explore therapeutic antibodies for neurodegenerative diseases.
- Diagnostic tools for early detection of biomarkers associated with neurodegenerative diseases.
- Engagement in partnerships for the advancement of research and development in neurodegenerative disease therapies.
equipe executiva do ProMIS Neurosciences
- Eugene W. WilliamsCo-Founder & Chairman
- Neil K. WarmaCEO, President, Compliance Officer & Director
- Neil R. CashmanCo-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
- Johanne KaplanChief Development Officer
- Larry Douglas AltstielChief Medical Officer
- Daniel E. GeffkenChief Financial Officer
- David WishartChief Physics Officer
- Dennis ChenHead of Manufacturing & Senior Consultant
- Ivana RubinoChief Commercial Officer
Últimas notícias sobre a ProMIS Neurosciences
Principais indicadores financeiros
Resultados divulgados pela ProMIS Neurosciences, em USD.
- Cap. de mercado
- 97,5 mi
- Receita (TTM)
- 7,6 mil
- P/L
- —
- LPA (diluído, TTM)
- -11.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -40,2 mi | -39,7 mi | |
| 0 | -16,8 mi | 2,8 mi | |
| 0 | -18,9 mi | -17,5 mi | |
| 8,1 mil | -23,4 bi | -18,1 bi |